FTC Orders Akorn To Sell Drug Lines For $640M Merger
The Federal Trade Commission on Monday approved Akorn Inc.'s $640 million acquisition of Long Island, N.Y.-based Hi-Tech Pharmacal Co. Inc. on the condition that the pharmaceutical companies sell five generic prescription...To view the full article, register now.
Already a subscriber? Click here to view full article